NEWS & EVENTS

CIBSS in den Medien

Artikel und Links zu Nachrichten über CIBSS und CIBSS-Mitglieder in Online-Medien, Zeitungen, Radio und Fernsehen. Wir verlinken auf die jeweilige Website, wenn der Artikel online verfügbar ist.

· Badische Zeitung

Freiburger Arzt über neue Prostatakrebs-Behandlung: "Das ist der entscheidende Fortschritt"

Prostatakrebs: Die häufigste Krebsart beim Mann. Warum die Drüse im Alter zum Problem wird, erklärt Roland Schüle von der Freiburger Uniklinik. Sein Team arbeitet an einem neuen Stoff, um den Krebs zu stoppen.

badische-zeitung.de
· Tech Explorist

New prostate cancer inhibitor holds massive promise

Cell-active inhibitor designed for methyltransferase KMT9.

The study focuses on developing a selective inhibitor targeting the methyltransferase KMT9. Methyltransferases play a crucial role in various cellular processes, and KMT9 has been identified as a potential therapeutic target, particularly in the context of diseases like cancer.

techexplorist.com
· The Paradise

New prostate cancer inhibitor holds massive promise

The study focuses on developing a selective inhibitor targeting the methyltransferase KMT9. Methyltransferases play a crucial role in various cellular processes, and KMT9 has been identified as a potential therapeutic target, particularly in the in the context of diseases like cancer.

https://theparadise.ng/18215/new-prostate-cancer-inhibitor-holds-massive-promise/
· Verve Times

Newly-developed inhibitor for prostate cancer demonstrates significant potential

In Germany, more than 65,000 men are diagnosed with prostate cancer each year, with 12,000 of them developing a treatment-resistant form that can lead to death. Researchers from the Medical Faculty at the University of Freiburg have developed a new active substance, KMI169, which targets an enzyme involved in the development of prostate cancer. This inhibitor has shown promise in combating resistant cancer cells.

vervetimes.com
· NewsConcerns

Prostate cancer: Newly-developed inhibitor shows massive potential

More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option. This substance, known as KMI169, targets an enzyme that plays an important role in the development of prostate cancer. The inhibitor displayed massive potential in among others cancer cells that were resistant to conventional treatments.

newsconcerns.com
· Pledge Times

Obesity: EPAC1 protein that increases brown fat identified

Obesity: why brown fat matters

The long-term goal of the study is to find drugs that support weight loss. Obesity is defined as a pathological increase in white fat and has become a major problem worldwide, with a significantly increased risk of cardiovascular diseases such as heart attack and stroke.

pledgetimes.com
· Oncology Nursing News

Ruxolitinib May Improve Control vs. Best Available Treatment in Steroid Refractory/Dependent cGVHD

After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.

oncnursingnews.com
· BNN

Decoding the Brain’s Code: New Research Promises to Revolutionize Neuroprosthetics

An interdisciplinary team of researchers at the University of Freiburg has unlocked significant findings on the functioning of the sensorimotor cortex. These discoveries hold the potential to revolutionize the development of neuroprosthetic devices, designed to interface with the nervous system and compensate for neuronal dysfunctions.

bnnbreaking.com
· Ärztliche Praxis Neurologie und Psychiatrie

Neue Landkarte des Immunsystems an Grenzregionen des Gehirns erstellt

Freiburger Forschende haben die zelluläre Zusammensetzung der Immunbarriere des Gehirns neu definiert. Die Studie ist im Fachmagazin “Nature Medicine” erschienen.

biermann-medizin.de/
· innovations report

Neue Landkarte des Immunsystems an Grenzregionen des Gehirns erstellt

Das Gehirn ist durch mehrere Barrieren vor potenziell schädlichen Einflüssen der Außenwelt abgegrenzt. Forscher*innen der Medizinischen Fakultät der Universität Freiburg gelang die Erstellung eines neuartigen Immunzellatlas dieser Grenzzonen des Gehirns mittels neuester, hochauflösender Methoden zur Untersuchung von Einzelzellen.

innovations-report.de